This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Momotaro-Gene Inc., Okayama University. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 10 
1 out of 138 
Years Active: 2017
Title: Kazuhiko Ochiai: Innovator in Cancer Immunotherapy
Introduction
Kazuhiko Ochiai is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer immunotherapy through his innovative research and patents. His work focuses on the development of polypeptides that can enhance the immune response against cancer.
Latest Patents
Kazuhiko Ochiai holds a patent for a "Partial region polypeptide of REIC/Dkk-3 protein." This polypeptide is capable of strongly inducing and activating dendritic-cell-like cells, which are crucial for treating or preventing cancer through immunotherapy. The patent also includes DNA encoding the polypeptide, which consists of a partial region of the REIC/Dkk-3 protein.
Career Highlights
Throughout his career, Kazuhiko Ochiai has worked with esteemed institutions such as Okayama University and Momotaro Gene Inc. His research has been pivotal in advancing the understanding of cancer treatment options.
Collaborations
Kazuhiko has collaborated with notable colleagues, including Hiromi Kumon and Masami Watanabe. Their joint efforts have contributed to the development of innovative solutions in cancer therapy.
Conclusion
Kazuhiko Ochiai's work in cancer immunotherapy exemplifies the impact of innovative research on medical science. His contributions continue to pave the way for new treatment options for cancer patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile